Exhibitors Search
Super Medical Technologies
Booth no.
B63
|
Exhibition
|
|KOREA LIFE SCIENCE |
|---|---|
|
Country
|
| Korea, South |
|
Address
|
|181 Gasan digital 1-ro, Geumcheon-gu, Seoul, Republic of Korea |
|
Tel
|
|+82-2-6297-0527 |
|
Exhibits
|
| allogeneic NK cell |
|
Company Type
|
| Pharmaceutical / Drug Development Company , Biotech Venture / Startup , Regenerative Medicine Company |
Exhibitor Information
SMT BIO is a biotechnology company specializing in cell therapy, with a focus on NK cell-based anticancer immunotherapies, cell supply, and SVF-related businesses.
Our lead pipeline, SMT-NK, is an allogeneic NK cell therapy for advanced biliary tract cancer. Following the completion of a Phase 1/2a clinical trial, SMT-NK is currently being evaluated in a Phase 2b clinical trial. Through clinical trials and approved compassionate use, three complete responses (CRs) and one partial response (PR) have been observed.
SMT BIO also supplies NK cells and stem cells for research and clinical applications, supported by established manufacturing and quality control systems. In addition, we are engaged in SVF (Stromal Vascular Fraction)-related activities in the fields of cell-based research and regenerative medicine.
Our lead pipeline, SMT-NK, is an allogeneic NK cell therapy for advanced biliary tract cancer. Following the completion of a Phase 1/2a clinical trial, SMT-NK is currently being evaluated in a Phase 2b clinical trial. Through clinical trials and approved compassionate use, three complete responses (CRs) and one partial response (PR) have been observed.
SMT BIO also supplies NK cells and stem cells for research and clinical applications, supported by established manufacturing and quality control systems. In addition, we are engaged in SVF (Stromal Vascular Fraction)-related activities in the fields of cell-based research and regenerative medicine.
Exhibit Description
SMT-NK is an allogeneic NK cell therapy under development for advanced biliary tract cancer, based on proprietary donor selection and NK cell culture/manufacturing technologies. A Phase 1/2a clinical trial has been completed, and a Phase 2b trial is currently ongoing. Across clinical trials and approved compassionate use, three complete responses (CRs) and one partial response (PR) have been observed.
Our cell supply business provides NK cells and stem cells for research and clinical applications, supported by established culture, manufacturing, and quality control capabilities.
SVF (Stromal Vascular Fraction) is isolated from adipose tissue and contains various vascular and stromal cell populations for use in research and regenerative medicine-related applications.
Our cell supply business provides NK cells and stem cells for research and clinical applications, supported by established culture, manufacturing, and quality control capabilities.
SVF (Stromal Vascular Fraction) is isolated from adipose tissue and contains various vascular and stromal cell populations for use in research and regenerative medicine-related applications.
Individual Exhibit/Technology Introduction (Detailed)
-
Product Name : SMT-NK, an allogeneic NK cell therapy**SMT-NK** is SMT BIO’s lead allogeneic NK cell therapy under development for advanced biliary tract cancer. It is based on proprietary donor selection technology and NK cell culture and manufacturing technologies. A Phase 1/2a clinical trial has been completed, and a Phase 2b clinical trial is currently ongoing. Through clinical trials and approved compassionate use, **three complete responses (CRs) and one partial response (PR) have been observed**. SMT-NK also utilizes a non-cryopreserved NK cell manufacturing process designed to maintain product quality while facilitating handling and clinical use, distinguishing it as an NK cell-based anticancer immunotherapy.
KYUNGYON EXHIBITION CORP.
